eligibility_summary
Eligibility: Adults ≥18 (ECOG ≥2), DLBCL NOS, HGBL (double/triple-hit or NOS), or EBV+ DLBCL, early relapse ≤12 mo after R+anthracycline first-line or refractory to last therapy, ≥1 Lugano-measurable/evaluable lesion, adequate marrow/organ function, LVEF ≥50%, negative pregnancy test/contraception, life expectancy >3 mo. Exclude PMBCL/primary or secondary CNS, HLH, active infection, severe comorbidity, recent trial therapy, stroke (6 mo), DVT/PE (12 mo), other recent cancer, HIV, uncontrolled HBV/HCV, major surgery (28 d), strong CYP1A2/3A use, need dual antiplatelet+anticoagulant, allergy, or investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06086197 tests A-RGEMOX (anlotinib + rituximab + gemcitabine + oxaliplatin) in early relapsed/primary refractory DLBCL (single-arm phase II). Drugs and mechanisms: Anlotinib—oral small-molecule multi–tyrosine kinase inhibitor (antiangiogenic) blocking VEGFR2/3, FGFR1–4, PDGFR and related signaling to suppress tumor neovascularization, may also inhibit tumor cell proliferation. Rituximab—chimeric anti-CD20 monoclonal antibody depleting B cells via ADCC, CDC, and apoptosis. Gemcitabine—antimetabolite nucleoside analog inhibiting ribonucleotide reductase and DNA synthesis (S-phase cytotoxicity). Oxaliplatin—platinum alkylating-like agent forming DNA crosslinks, inducing apoptosis. Targets: CD20+ malignant B cells, DNA synthesis/repair in proliferating lymphoma cells, tumor vasculature via VEGF/PDGF/FGF pathways.